Antimicrobial resistance mechanisms

Resistance is intrinsic, acquired, and selected by exposure

Intrinsic resistance is predictable from organism biology, such as Enterococcus resistance to cephalosporins or anaerobe resistance to aminoglycosides. Acquired resistance appears through mutation or horizontal gene transfer. Antibiotic exposure then selects organisms or subpopulations that can survive. The ecological lesson is practical: unnecessary antibiotics, prolonged courses, underdosing, high-burden infection, and delayed source control all increase selection pressure.

• Mutation: target changes such as gyrA/parC fluoroquinolone resistance or rpoB rifampin resistance.
• Horizontal transfer: plasmid-mediated ESBLs, carbapenemases, aminoglycoside-modifying enzymes, qnr, and mcr.
• Mobile elements: plasmids, transposons, integrons, and resistance islands can cluster multiple mechanisms.
• Selection: treating colonization and leaving uncontrolled sources are resistance accelerants.

Drug inactivation is the classic enzymatic mechanism

Bacteria can destroy or modify antibiotics before the drug reaches its target. Beta-lactamases hydrolyze beta-lactams. Aminoglycoside-modifying enzymes acetylate, adenylate, or phosphorylate aminoglycosides. Chloramphenicol acetyltransferase inactivates chloramphenicol. The clinical mistake is treating all enzymes as equivalent. Enzyme class, organism, drug, inhibitor, inoculum, and infection site determine whether a drug is reliable.

• Ambler A: serine beta-lactamases including many ESBLs and KPC.
• Ambler B: metallo-beta-lactamases such as NDM, VIM, and IMP; not inhibited by avibactam, vaborbactam, or relebactam alone.
• Ambler C: AmpC enzymes, inducible or derepressed in several Enterobacterales.
• Ambler D: OXA enzymes, including OXA-48-like carbapenemases.

Target alteration lowers drug binding

If the target changes, an otherwise active drug may no longer bind. MRSA produces PBP2a encoded by mecA, lowering affinity for most beta-lactams. VRE remodels peptidoglycan termini from D-Ala-D-Ala to D-Ala-D-Lac, reducing vancomycin binding. Macrolide and clindamycin resistance can occur through erm-mediated ribosomal methylation. Fluoroquinolone resistance commonly involves DNA gyrase or topoisomerase IV mutations. Rifampin resistance can emerge through rpoB mutations.

• MRSA: altered PBP, not an ESBL problem.
• VRE: altered cell-wall precursor terminus, not vancomycin destruction.
• MLSB resistance: ribosomal methylation can affect macrolides, lincosamides, and streptogramin B.
• Fluoroquinolones/rifampin: target mutations can emerge quickly under selection pressure.

Target protection and target bypass preserve essential pathways

Some resistance mechanisms protect the target without replacing it. Tet(M) and related ribosomal protection proteins dislodge tetracyclines from the ribosome. Qnr proteins protect DNA gyrase and topoisomerase IV from fluoroquinolones. Other organisms bypass the inhibited pathway by using alternative enzymes, such as sul and dfr genes that reduce TMP-SMX activity. These mechanisms may combine with efflux, permeability changes, and enzymatic resistance.

• Target protection: tetracycline ribosomal protection and Qnr-mediated fluoroquinolone protection.
• Target bypass: alternative folate enzymes for sulfonamide or trimethoprim resistance.
• Clinical implication: low-level protection mechanisms can become high-level resistance when layered with other mechanisms.

Reduced permeability and efflux are central gram-negative defenses

Gram-negative organisms add an outer membrane barrier. Drugs must enter through porins or cross membranes, avoid periplasmic enzymes, and remain near the target. Porin loss can reduce entry of beta-lactams and carbapenems. Efflux pumps actively remove antibiotics and can affect tetracyclines, macrolides, fluoroquinolones, beta-lactams, and multiple unrelated classes. Pseudomonas is the classic organism where low permeability, efflux, AmpC, and target changes combine.

• Porin loss plus ESBL or AmpC can cause carbapenem resistance without a carbapenemase.
• Efflux can create multidrug resistance because one pump may export several classes.
• DTR Pseudomonas often reflects layered mechanisms, not one simple mutation.

ESBL, AmpC, and CRE are different beta-lactam resistance problems

ESBLs hydrolyze many penicillins and cephalosporins and make ceftriaxone unreliable for serious infection even when reports appear tempting. AmpC enzymes may be inducible or derepressed in organisms such as Enterobacter cloacae complex, Klebsiella aerogenes, and Citrobacter freundii; third-generation cephalosporin therapy can select resistance during invasive infection. CRE may reflect KPC, OXA-48-like, metallo-beta-lactamase, or non-carbapenemase mechanisms, and preferred therapy depends on the mechanism and susceptibility.

• ESBL-E: think ceftriaxone failure risk in invasive infection.
• AmpC-E: avoid ceftriaxone for invasive disease with moderate-risk organisms even if initially susceptible.
• CRE: request or review mechanism testing when available because therapy differs by enzyme.
• Do not treat all beta-lactamases as one category.

Ribosomal resistance includes drug modification, methylation, protection, and efflux

Aminoglycoside resistance commonly reflects aminoglycoside-modifying enzymes, reduced uptake, or 16S rRNA methylation. Tetracycline resistance often reflects efflux pumps, ribosomal protection proteins, or enzymatic inactivation such as Tet(X). Macrolide and clindamycin resistance may reflect erm-mediated ribosomal methylation; the D-test detects inducible clindamycin resistance when erythromycin resistance is present. Linezolid resistance may involve 23S rRNA mutations or transferable genes such as cfr, optrA, and poxtA.

• Aminoglycosides: modifying enzymes are common; 16S methylation can cause high-level resistance.
• Tetracyclines: efflux and ribosomal protection are classic.
• Macrolide/clindamycin: erm methylation can be inducible or constitutive.
• Linezolid: watch for resistance with prolonged exposure and VRE pressure.

Glycopeptide, daptomycin, polymyxin, fosfomycin, and cefiderocol resistance are mechanism-specific

VRE usually resists vancomycin by replacing D-Ala-D-Ala with D-Ala-D-Lac, reducing glycopeptide binding. VISA/VRSA in S. aureus involve different biology and are rare but important. Daptomycin resistance often involves altered membrane charge or homeostasis. Polymyxin resistance can result from lipid A modification, including plasmid-mediated mcr genes. Fosfomycin resistance may reflect transporter changes, MurA changes, or Fos enzymes. Cefiderocol resistance may involve siderophore transport changes, beta-lactamases, or permeability changes.

• VRE: target remodeling; linezolid or daptomycin decisions depend on syndrome and susceptibility.
• Daptomycin: resistance risk rises with high-burden infection and poor source control.
• Polymyxins: lipid A modification reduces binding.
• Cefiderocol: iron-transport biology means resistance can involve siderophore pathway changes.

Biofilm and persistence are source-control problems as much as drug problems

Biofilm on catheters, prosthetic joints, valves, cardiac devices, stones, and necrotic tissue creates a protected microbial community with altered metabolism and reduced antimicrobial susceptibility. Persister cells are phenotypically tolerant rather than genetically resistant, but the clinical effect can be relapse if the infected focus remains. Antibiotic escalation rarely solves an undrained abscess, obstructed urinary tract, infected catheter, or devitalized tissue by itself.

• Remove or exchange infected hardware when feasible and clinically indicated.
• Drain abscesses and relieve obstruction early.
• Do not confuse persistent positive cultures from poor source control with the need for endlessly broader antibiotics.

Susceptibility reports are phenotypes, not complete mechanism reports

The susceptibility table reflects standardized testing and breakpoint interpretation. It does not automatically report mechanism, tissue penetration, inoculum effect, biofilm activity, source control, toxicity, or whether a drug is appropriate for the syndrome. Intermediate or susceptible-dose-dependent results may require higher exposure. Some drugs are reported because they are useful for cystitis but are wrong for pyelonephritis or bacteremia. When CRE, DTR Pseudomonas, VRE bacteremia, or discordant results appear, call the microbiology lab early.

• Read organism identity before the drug rows.
• Know the site: urine-only drugs are not bloodstream drugs.
• Ask for mechanism testing when it will change therapy.
• Treat infection, not colonization or culture positivity alone.

Guidelines

• IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative InfectionsInfectious Diseases Society of America, current online guidance.Practical treatment guidance for ESBL-E, AmpC-E, CRE, and difficult-to-treat Pseudomonas.
• CLSI: Standards for Antimicrobial Susceptibility TestingClinical and Laboratory Standards Institute M100 performance standards, current edition.Breakpoint interpretation, susceptibility categories, and standardized antimicrobial susceptibility testing framework.

Reviews

• Action and resistance mechanisms of antibiotics: a guide for cliniciansKapoor G, Saigal S, Elongavan A. J Anaesthesiol Clin Pharmacol. 2017;33(3):300-305. PMID: 29109626. DOI: 10.4103/joacp.JOACP_349_15.Short clinician-friendly companion review for mechanisms of action and major resistance pathways.
• A primer on AmpC beta-lactamases: necessary knowledge for an increasingly multidrug-resistant worldTamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ. Clin Infect Dis. 2019;69(8):1446-1455.Focused explanation of AmpC biology, inducible resistance, and clinical treatment traps.

Books & reference

• Molecular Mechanisms of Antibiotic Resistance in BacteriaPerez F, Stiefel U, Bonomo RA. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Ch. 18.Authoritative textbook chapter for beta-lactamases, permeability, efflux, target alteration, mobile genetic elements, and clinically important resistance phenotypes.